# Akero Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akero-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.akerotx.com
- Total disclosed funding: $135M
- Latest round: Series B (Dec 10, 2018)
- Investors on record: 11

## About

Founded in 2017 and based in California, US, Akero Therapeutics, Inc. operates as a biotechnology that develops treatment of non-alcoholic steatohepatitis and other metabolic disorders that target the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis. In March 2024, Akero Therapeutics Inc. raised USD 319 million in a private placement, selling 11 million shares at USD 29 per share on the Nasdaq Global Select Market under the ticker symbol "AKRO". Akero Therapeutics Inc. has granted the underwriters a 30-day option to purchase up to an additional 1.65 million shares of common stock as part of the listing.

Akero Therapeutics developes therapies for serious metabolic diseases, to improve patients' lives. The company with its lead program, Efruxifermin (EFX), focuses on addressing metabolic dysfunction-associated steatohepatitis (MASH).

## Funding rounds

- Series B, Dec 10, 2018, $70M — Atlas Venture, Versant Ventures, Apple Tree Partners, Redmile Group, VenBio, BVF Partners, Rock Springs Capital, Cormorant Asset Management, Janus Henderson Investors, Boxer Capital, LifeSci Partners
- Series A, Jun 23, 2018, $65M — Atlas Venture, Versant Ventures, Apple Tree Partners, VenBio

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A, Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B
- Rock Springs Capital — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Janus Henderson Investors — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B